Cupid Ltd. Reports Robust Earnings for Q3FY24, PAT Grows 73% QoQ

▴ CUPID Limited
Board of Directors approved a stock split of 10:1 and a bonus share issue of 1:1 in order to enhance shareholder value further. With this decision, we are ensuring that our shareholders' interests are aligned with ours.

Q3FY24 – Earnings Update

Chennai, 24 January 2024: Cupid Ltd., India's premier manufacturer of male and female condoms, water-based lubricant jelly, and IVD kits, in its board meeting held on January 23, 2024 has approved the unaudited Financial Results of the Company for the quarter and nine months ended on 31 December 2023. The board further approved stock split in the ratio of 10:1, i.e. split of 1 share of Rs. 10 each into 10 shares of Re.1 each, and a bonus issue of equity shares in the ratio of 1:1, i.e. 1 Equity Shares of Re. 1 each for every 1 Equity Share of Re. 1/- each held by the shareholders of the Company as on the Record Date, subject to all statutory and shareholder approvals. The board also approved the issue of Convertible warrants on Preferential basis to FIIs for Rs. 385 crores.

Standalone Financial Statement Highlights for Q3FY24 vs Q2FY24 vs Q3FY23

Particulars (Rs. Crores except EPS)

Q3FY24

Q2FY24

QoQ%

Q3FY23

Revenue from Operations

40.05

34.46

16%

41.76

Total Expenses excluding Depreciation, Amortization & Finance Cost

 

 

 

 

27.9

29.24

 

28.85

EBITDA

12.15

5.22

132%

12.91

EBITDA Margin (%)

30.34%

15.15%

1519 bps

30.91%

Depreciation & Amortization

0.75

0.72

 

0.77

Finance Cost

0.39

0.07

 

0.07

Other Income

0.72

1.98

 

1.15

PBT before Exceptional Item

11.73

6.41

 

13.22

Exceptional Items

0

0

 

0

PBT

11.73

6.41

83%

13.22

Tax

2.87

1.3

 

3.19

PAT

8.86

5.11

73%

10.03

PAT Margin %

22.12%

14.83%

729 bps

24.02%

Basic EPS

6.65

3.84

 

7.52

 

 

Standalone Financial Performance Comparison Q2FY24 v/s Q3FY24

·         Revenue from Operations grew by 16% from Rs. 34.46 Cr in Q2FY24 to Rs. 40.05 Cr in Q3FY24.

·         EBITDA increased by 132% from Rs. 5.22 Cr in Q2FY24 to Rs. 12.15 Cr in Q3FY24

·         PAT increased by 73% from Rs. 5.11 Cr in Q2FY24 to Rs. 8.86 Cr in Q3FY24.

 

Management Comments

Commenting on the Q3FY24 Performance, Management added,

“We are pleased to announce the financial results for the third quarter of the fiscal year 2023-24, reflecting a robust performance across key financial indicators. Our Revenue from Operations witnessed a commendable growth of 16%, reaching Rs. 40.05 Cr in Q3FY24, compared to Rs. 34.46 Cr in the preceding quarter. This growth underscores our resilient business model and effective execution of our strategic initiatives.

A significant improvement was evident in our EBITDA, which surged from Rs. 5.22 Cr in Q2FY24 to Rs. 12.15 Cr in Q3FY24 by 132%..

Furthermore, the  Profit After Tax (PAT) registered a noteworthy increase of 73%, climbing from Rs. 5.11 Cr in Q2FY24 to Rs. 8.86 Cr in Q3FY24.

Additionally, we are delighted to share the exciting news of our recent acquisition of a new land parcel in the MIDC Area, first announced in December 2023. This strategic move is poised to significantly enhance our production capabilities, solidifying our position in the global market. The acquisition will augment our production capacity by 1.5 times the existing output, enabling us to produce approximately 770 million male condoms and 75 million female condoms annually, in addition to our current capacity of 480 million male condoms and 50 million female condoms.

Board of Directors approved a stock split of 10:1 and a bonus share issue of 1:1 in order to enhance shareholder value further. With this decision, we are ensuring that our shareholders' interests are aligned with ours.

Finally the Board has approved the preferential issue of 22,00,000 convertible warrants totaling Rs. 385 crores. These warrants are proposed to be allocated to reputed entities such as Forbes EMF, Elara India Opportunities Fund Limited, Aries Opportunities Fund Limited, Arrow Emerging Opportunities Fund Limited, Zeal Global Opportunities Fund, Nova Global Opportunities Fund PCC Touchstone. The preferential issue is priced at Rs. 1750 per warrant. The capital infusion will help us strengthen our financial position and support our ambitious growth plans. The collaboration with these esteemed investors underscores their confidence in our business and future prospects.

We remain optimistic about the future and are confident that these strategic initiatives will contribute to sustained growth, solidifying our position. We appreciate the continued support of our shareholders, customers, and stakeholders as we pursue our commitment to excellence and value creation.”

    About Cupid Ltd.

Established in 1993, CUPID Limited is India's premier manufacturer of male and female condoms, water-based lubricant jelly, and IVD kits. The company boasts a production capacity of up to 480 million male condoms, 52 million female condoms, 210 million sachets of lubricant jelly and 20 million IVD Test Kits annually. In December 2023, the company announced strategic land acquisition that will enable it to amplify its production capacity by 1.5 times the existing output. As a result, the annual production capacity will be augmented by approximately 770 million male condoms and 75 million female condoms. This expansion is in addition to the current production capacity. The company has a prominent presence in the international markets and holds the distinction of being the first company in the world to attain WHO/UNFPA pre-qualification for male and female condoms. CUPID currently exports its products to over 105 countries, with over 90% of its revenue generated from international markets. Furthermore, CUPID has established a long-term agreement with WHO/UNFPA. The company is listed on BSE (BSE: 530843) and NSE (NSE: CUPID)

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Clinical Interventions in Chronic Hepatitis B and C: Antiviral Efficacy, Liver Fibrosis Scoring, and Monitoring August 11, 2026
Common Health Mistakes Indians Should Avoid: A Practical Guide to Everyday WellnessAugust 11, 2026
How to Build a Healthy Lifestyle After 40: A Practical Guide for Indian AdultsAugust 11, 2026
Milk Microbiome Could Hold New Clues to Lifelong Health, Experts SayAugust 10, 2026
Globally Renowned Dermatologist and Sesderma Founder Professor Dr. Gabriel Serrano to Visit India to Showcase Cutting-Edge Derma-Tech for Indian Skincare at Scientific Symposiums Hosted by Iberia PharmaceuticalsAugust 10, 2026
Sharda Hospital Celebrates World Breastfeeding Week with a Week-Long Awareness ProgrammeAugust 10, 2026
Swinburne University of Technology Opens Applications for Master of Engineering ScienceAugust 10, 2026
GLP-1 Receptor Agonists: A New Era in Weight Loss TreatmentAugust 10, 2026
Immunotherapy vs. Chemotherapy: Understanding the Mechanisms of Precision OncologyAugust 10, 2026
Mitigating Tech-Induced Ailments: Managing Screen Time, Sedentary Lifestyles, and Dry Eye SyndromeAugust 10, 2026
The Blueprint of Validation: Navigating Medical AI’s "Reckoning Year"August 10, 2026
The Future of Smart Hospitals: Redefining Healthcare Delivery in India August 10, 2026
Healthcare Data Security in India: Risks, Threats, and Best Practices for a Digital-First Health EcosystemAugust 10, 2026
The Science of Resilience: Psychological Strategies for Modern StressAugust 08, 2026
The Science of Fasting: 2026 Research on Autophagy and LongevityAugust 08, 2026
Early Markers of Insulin Resistance: Moving Beyond Fasting Blood SugarAugust 08, 2026
Healthcare Management Challenges in India: What Hospital Leaders Must Address NowAugust 08, 2026
Importance of Patient Safety: Why Every Hospital in India Must Prioritize ItAugust 08, 2026
Decoding Fatty Liver Disease: Symptoms, Reversibility, and the MASLD/NAFLD SpectrumAugust 07, 2026
Heart-Healthy Dietary Patterns: Translating Clinical Nutrition Guidelines into Daily MealsAugust 07, 2026